|Title||How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?|
|Publication Type||Journal Article|
|Year of Publication||2023|
|Authors||Juckett, M, Dandoy, C, DeFilipp, Z, Kindwall-Keller, TL, Spellman, SR, Ustun, C, Waldman, BM, Weisdorf, DJ, Wood, WA, Horowitz, MM, Burns, LJ, Khera, N|
|Date Published||2023 Apr 07|
The field of hematopoietic cell transplantation and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant diseases. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice. In this review, we describe the potential factors based on an implementation framework that could act as facilitators or barriers to adoption of therapies in the context of HCT/CT. We highlight two examples, the first to showcase the efforts to improve the efficiency of adoption of new findings and accelerate improvement in care of HCT/CT patients and the second to discuss the challenges in real world implementation of chimeric antigen receptor T cell therapy. We conclude by reviewing strategies to improve translation of evidence and ways to measure their success.
|Alternate Journal||Blood Rev|